

Sabra Health Care REIT, Inc.
Form 10-Q
August 08, 2018
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-34950

SABRA HEALTH CARE REIT, INC.
(Exact Name of Registrant as Specified in Its Charter)

Maryland 27-2560479
(State of Incorporation) (I.R.S. Employer Identification No.)
18500 Von Karman Avenue, Suite 550
Irvine, CA 92612
(888) 393-8248
(Address, zip code and telephone number of Registrant)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer
Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: Sabra Health Care REIT, Inc. - Form 10-Q

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 2, 2018, there were 178,283,590 shares of the registrant's \$0.01 par value Common Stock outstanding.

Table of Contents

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

Index

	Page Numbers
<u>PART I. FINANCIAL INFORMATION</u>	
Item 1. <u>Financial Statements:</u>	
<u>Condensed Consolidated Balance Sheets</u>	4
<u>Condensed Consolidated Statements of Income</u>	5
<u>Condensed Consolidated Statements of Comprehensive Income</u>	6
<u>Condensed Consolidated Statements of Equity</u>	7
<u>Condensed Consolidated Statements of Cash Flows</u>	8
<u>Notes to Condensed Consolidated Financial Statements</u>	9
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	41
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	56
Item 4. <u>Controls and Procedures</u>	56
<u>PART II. OTHER INFORMATION</u>	
Item 1. <u>Legal Proceedings</u>	58
Item 1a. <u>Risk Factors</u>	58
Item 6. <u>Exhibits</u>	58
<u>Signatures</u>	59

Table of Contents

References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.

STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q (this “10-Q”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:

- our dependence on the operating success of our tenants;
- operational risks with respect to our Senior Housing - Managed communities (as defined below);
- the effect of our tenants declaring bankruptcy or becoming insolvent;
- our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;
- the impact of litigation and rising insurance costs on the business of our tenants;
- our ability to implement the previously announced rent repositioning program for certain of our tenants who were legacy tenants of Care Capital Properties, Inc. (“CCP”) on the timing or terms we have previously disclosed;
- our ability to dispose of facilities currently leased to Genesis Healthcare, Inc. (“Genesis”) on the timing or terms we have previously disclosed;
- the possibility that Sabra may not acquire the remaining majority interest in the Enlivant Joint Venture (as defined below);
- risks associated with our investments in joint ventures;
- changes in healthcare regulation and political or economic conditions;
- the impact of required regulatory approvals of transfers of healthcare properties;
- competitive conditions in our industry;
- our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;
- the significant amount of and our ability to service our indebtedness;
- covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;
- increases in market interest rates;
- our ability to raise capital through equity and debt financings;
- changes in foreign currency exchange rates;
- the relatively illiquid nature of real estate investments;
- the loss of key management personnel or other employees;
- uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities;
 - the impact of a failure or security breach of information technology in our operations;
- our ability to maintain our status as a real estate investment trust (“REIT”);
- changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act);
- compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and
-

the ownership limits and anti-takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities.

We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2017 (our "2017 Annual Report on Form 10-K"), as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the "SEC"), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this

Table of Contents

10-Q are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-Q or to reflect the occurrence of unanticipated events, unless required by law to do so.

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)

	June 30, 2018 (unaudited)	December 31, 2017
Assets		
Real estate investments, net of accumulated depreciation of \$377,159 and \$340,423 as of June 30, 2018 and December 31, 2017, respectively	\$5,993,682	\$ 5,994,432
Loans receivable and other investments, net	107,228	114,390
Investment in unconsolidated joint venture	348,950	—
Cash and cash equivalents	38,809	518,632
Restricted cash	186,845	68,817
Lease intangible assets, net	156,266	167,119
Accounts receivable, prepaid expenses and other assets, net	196,364	168,887
Total assets	\$7,028,144	\$ 7,032,277
Liabilities		
Secured debt, net	\$253,567	\$ 256,430
Revolving credit facility	676,000	641,000
Term loans, net	1,187,398	1,190,774
Senior unsecured notes, net	1,306,842	1,306,286
Accounts payable and accrued liabilities	105,339	102,523
Lease intangible liabilities, net	91,073	98,015
Total liabilities	3,620,219	3,595,028
Commitments and contingencies (Note 13)		
Equity		
Preferred stock, \$.01 par value; 10,000,000 shares authorized, 5,750,000 shares issued and outstanding as of December 31, 2017	—	58
Common stock, \$.01 par value; 250,000,000 shares authorized, 178,283,590 and 178,255,843 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	1,783	1,783
Additional paid-in capital	3,502,954	3,636,913
Cumulative distributions in excess of net income	(125,606)	(217,236)
Accumulated other comprehensive income	24,412	11,289
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543	3,432,807
Noncontrolling interests	4,382	4,442
Total equity	3,407,925	3,437,249
Total liabilities and equity	\$7,028,144	\$ 7,032,277

See accompanying notes to condensed consolidated financial statements.

Table of Contents

SABRA HEALTH CARE REIT, INC.
 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
 (dollars in thousands, except per share data)
 (unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2018	2017	2018	2017
Revenues:				
Rental income	\$144,229	\$55,904	\$288,484	\$113,128
Interest and other income	4,553	2,027	8,891	3,972
Resident fees and services	17,530	6,805	35,023	10,286
Total revenues	166,312	64,736	332,398	127,386
Expenses:				
Depreciation and amortization	46,828	17,220	94,833	36,357
Interest	36,757	15,862	72,575	31,650
Operating expenses	12,299	4,407	24,423	6,827
General and administrative	9,271	5,126	17,138	11,215
Merger and acquisition costs	112	5,887	442	6,451
(Recovery of) provision for doubtful accounts and loan losses	(674)	535	539	2,305
Impairment of real estate	881	—	1,413	—
Total expenses	105,474	49,037	211,363	94,805
Other income:				
Other income	—	941	2,820	3,070
Net gain on sales of real estate	142,903	4,032	142,431	4,032
Total other income	142,903	4,973	145,251	7,102
Income before loss from unconsolidated joint venture and income tax expense	203,741	20,672	266,286	39,683
Loss from unconsolidated joint venture	(2,347)	—	(1,901)	—
Income tax expense	(605)	(136)	(1,115)	(356)
Net income	200,789	20,536	263,270	39,327
Net (income) loss attributable to noncontrolling interests	(2)	(16)	(12)	16
Net income attributable to Sabra Health Care REIT, Inc.	200,787	20,520	263,258	39,343
Preferred stock dividends	(7,207)	(2,560)	(9,768)	(5,121)
Net income attributable to common stockholders	\$193,580	\$17,960	\$253,490	\$34,222
Net income attributable to common stockholders, per:				

Edgar Filing: Sabra Health Care REIT, Inc. - Form 10-Q

Basic common share	\$1.09	\$ 0.27	\$1.42	\$0.52
Diluted common share	\$1.08	\$ 0.27	\$1.42	\$0.52
Weighted-average number of common shares outstanding, basic	178,314,750	178,438,739	178,304,733	178,396,146
Weighted-average number of common shares outstanding, diluted	178,684,024	178,670,853	178,600,789	178,694,019
Dividends declared per common share	\$0.45	\$ 0.43	\$0.90	\$0.85

See accompanying notes to condensed consolidated financial statements.

5

Table of Contents

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2018	2017	2018	2017
Net income	\$200,789	\$20,536	\$263,270	\$39,327
Other comprehensive income (loss):				
Unrealized gain (loss), net of tax:				
Foreign currency translation gain (loss)	261	698	(113)	140
Unrealized gain on cash flow hedges	3,338	97	13,236	825
Total other comprehensive income	3,599	795	13,123	965
Comprehensive income	204,388	21,331	276,393	40,292
Comprehensive (income) loss attributable to noncontrolling interest	(2)	(16)	(12)	16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	\$204,386	\$21,315	\$276,381	\$40,308

See accompanying notes to condensed consolidated financial statements.

SABRA HEALTH CARE REIT, INC.
 CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
 (dollars in thousands, except per share data)
 (unaudited)

	Preferred Stock		Common Stock			Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Noncontrolling Interests	Total Equity
	Shares	Amount	Shares	Amount	Amount						
Balance, December 31, 2016	5,750,000	\$58	65,285,614	\$653	\$1,208,862	\$(192,201)	\$(1,798)	\$1,015,574	\$35	\$1,015,609	
Net income (loss)	—	—	—	—	—	39,343	—	39,343	(16)	39,327	
Other comprehensive income	—	—	—	—	—	—	965	965	—	965	
Amortization of stock-based compensation	—	—	—	—	4,848	—	—	4,848	—	4,848	
Common stock issuance, net	—	—	139,820	1	(2,815)	—	—	(2,814)	—	(2,814)	
Preferred dividends	—	—	—	—	—	(5,121)	—	(5,121)	—	(5,121)	
Common dividends (\$0.85 per share)	—	—	—	—	—	(56,099)	—	(56,099)	—	(56,099)	
Balance, June 30, 2017	5,750,000	\$58	65,425,434	\$654	\$1,210,895	\$(214,078)	\$(833)	\$996,696	\$19	\$996,715	
	Preferred Stock		Common Stock			Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity	Noncontrolling Interests	Total Equity
	Shares	Amount	Shares	Amount	Amount						
Balance, December 31, 2017	5,750,000	\$58	178,255,843	\$1,783	\$3,636,913	\$(217,236)	\$11,289	\$3,432,807	\$4,442	\$3,437,249	
Cumulative effect of ASU 2017-12 adoption	—	—	—	—	—	(795)	795	—	—	—	
Net income	—	—	—	—	—	263,258	—	263,258	12	263,270	
Other comprehensive income	—	—	—	—	—	—	12,328	12,328	—	12,328	
	—	—	—	—	—	—	—	—	(72)	(72)	

Distributions to noncontrolling interests										
Amortization of stock-based compensation	—	—	—	—	4,434	—	—	4,434	—	4,434
Preferred stock redemption	(5,750,000)	(58)	—	—	(138,191)	(5,501)	—	(143,750)	—	(143,750)
Common stock issuance, net	—	—	27,747	—	(202)	—	—	(202)	—	(202)
Preferred dividends	—	—	—	—	—	(4,267)	—	(4,267)	—	(4,267)
Common dividends (\$0.90 per share)	—	—	—	—	—	(161,065)	—	(161,065)	—	(161,065)
Balance, June 30, 2018	—	\$—	178,283,590	\$1,783	\$3,502,954	\$(125,606)	\$24,412	\$3,403,543	\$4,382	\$3,407,922

See accompanying notes to condensed consolidated financial statements.

Table of Contents

SABRA HEALTH CARE REIT, INC.
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (in thousands)
 (unaudited)

	Six Months Ended June 30,	
	2018	2017
Cash flows from operating activities:		
Net income	\$263,270	\$39,327
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	94,833	36,357
Amortization of above and below market lease intangibles, net	(1,368)	—
Non-cash interest income adjustments	(1,174)	51
Non-cash interest expense	4,997	3,244
Stock-based compensation expense	3,839	4,319
Straight-line rental income adjustments	(23,752)	(9,578)
Provision for doubtful accounts and loan losses	539	2,305
Change in fair value of contingent consideration	—	(822)
Net gain on sales of real estate	(142,431)	(4,032)
Impairment of real estate	1,413	—
Loss from unconsolidated joint venture	1,901	—
Distributions of earnings from unconsolidated joint venture	3,610	—
Changes in operating assets and liabilities:		
Accounts receivable, prepaid expenses and other assets, net	(2,130)	(15,575)
Accounts payable and accrued liabilities	8,006	(1,314)
Net cash provided by operating activities	211,553	54,282
Cash flows from investing activities:		
Acquisition of real estate	(213,982)	(14,456)
Origination and fundings of loans receivable	(28,157)	(927)
Origination and fundings of preferred equity investments	(945)	(76)
Additions to real estate	(16,817)	(1,294)
Repayments of loans receivable	38,887	1,547
Repayments of preferred equity investments	375	2,766
Investment in unconsolidated joint venture	(354,461)	—
Net proceeds from the sales of real estate	278,201	6,099
Net cash used in investing activities	(296,899)	(6,341)
Cash flows from financing activities:		
Net borrowings from revolving credit facility	35,000	6,000
Principal payments on secured debt	(2,128)	(2,049)
Payments of deferred financing costs	(12)	(124)
Distributions to noncontrolling interests	(72)	—
Preferred stock redemption	(143,750)	—
Issuance of common stock, net	(499)	(3,224)
Dividends paid on common and preferred stock	(164,736)	(60,691)
Net cash used in financing activities	(276,197)	(60,088)

Edgar Filing: Sabra Health Care REIT, Inc. - Form 10-Q

Net decrease in cash, cash equivalents and restricted cash	(361,543)	(12,147)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(252)	130
Cash, cash equivalents and restricted cash, beginning of period	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	\$225,654	\$22,648
Supplemental disclosure of cash flow information:		
Interest paid	\$67,793	\$28,944
See accompanying notes to condensed consolidated financial statements.		

8

Table of Contents

SABRA HEALTH CARE REIT, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

1. BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra's separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the United States and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and Sabra’s wholly owned subsidiaries are currently the only limited partners, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

On May 7, 2017, the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, on August 17, 2017, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value \$0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value \$0.01 per share, plus cash in lieu of any fractional shares. See Note 3, “CCP Merger and Recent Real Estate Acquisitions” for additional information regarding the CCP Merger.

The acquisition of CCP has been reflected in the Company’s condensed consolidated financial statements since the effective date of the CCP Merger.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of June 30, 2018 and December 31, 2017 and for the periods ended June 30, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim

periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the Company's consolidated financial statements and notes thereto for the

Table of Contents

year ended December 31, 2017 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities ("VIEs"). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity's activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity's activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity's activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity's equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity's economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis.

As of June 30, 2018, the Company determined it was the primary beneficiary of two variable interest entities—one exchange accommodation titleholder variable interest entity and a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of these entities in the accompanying condensed consolidated financial statements. As of June 30, 2018, the Company determined that operations of these entities were not material to the Company's results of operations, financial condition or cash flows.

As it relates to investments in loans, in addition to the Company's assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower's expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At June 30, 2018, none of the Company's investments in loans are accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners' rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of June 30, 2018, the Company's determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company's consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated statements of income and condensed consolidated statements of cash flows.

Table of Contents

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company's share of the investee's earnings or losses is included in the Company's condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company's cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company's share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed \$352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owns 172 senior housing communities managed by Enlivant (the "Enlivant Joint Venture"). At closing, the Enlivant Joint Venture had outstanding indebtedness of \$791.3 million and net working capital of \$22.9 million, and the Company's investment in the Enlivant Joint Venture implied an aggregate portfolio value of \$1.49 billion. The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company's partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). In addition, Sabra has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. As of June 30, 2018, the book value of the Company's investment in the Enlivant Joint Venture was \$349.0 million.

Net Investment in Direct Financing Lease

As of June 30, 2018, the Company had a \$23.2 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments, plus the estimated unguaranteed residual value, less the unearned lease income. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company's net investment in direct financing lease was \$0.6 million and \$1.3 million for the three and six months ended June 30, 2018, respectively, and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at June 30, 2018, were as follows: \$1.1 million for the remainder of 2018; \$2.2 million for 2019; \$2.3 million for 2020; and \$2.1 million for 2021.

Recently Issued Accounting Standards Update

Adopted

Between May 2014 and February 2017, the FASB issued four Accounting Standards Updates (each, an "ASU") changing the requirements for recognizing and reporting revenue (together, herein referred to as the "Revenue ASUs"): (i) ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ("ASU 2016-08"), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients ("ASU 2016-12") and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets ("ASU 2017-05"). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or

services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. The Revenue ASUs became effective for the Company on January 1, 2018 with the Company electing to use the modified retrospective approach for its adoption. Further, the Company elected to reassess only contracts that were not completed as of the adoption date. The adoption of these ASUs did not have a material impact to beginning retained earnings as of January 1, 2018.

Table of Contents

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides specific guidance clarifying how certain cash receipts and payments should be classified. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-15 and ASU 2016-18 on January 1, 2018. The full retrospective approach of adoption is required for both ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported in the accompanying condensed consolidated statements of cash flows and as previously reported prior to the adoption (in thousands):

	Six Months Ended	
	June 30, 2017	
	As Reported	As Previously Reported
Net cash provided by operating activities	54,282	53,871
Net decrease in balance	(12,147)	(12,558)
Balance - beginning of the year	34,665	25,663
Balance - end of the year	22,648	13,235

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is intended to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements and to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company adopted ASU 2017-12 effective beginning January 1, 2018. ASU 2017-12 requires a modified retrospective transition method in which the Company recognized the cumulative effect of the change on the opening balance of each affected component of equity in the condensed consolidated balance sheet as of the date of adoption, which resulted in a decrease to cumulative distributions in excess of net income and an increase to accumulated other comprehensive income of \$0.8 million.

Issued but Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, entities currently are required to adopt the new lease requirements using a modified retrospective transition method whereby an entity initially applies the new lease requirements (subject to specific transition requirements and optional practical expedients) at the beginning of the earliest period presented in the financial statements. Upon adoption of ASU 2016-02, the Company will recognize its operating leases for which it is the lessee, mainly corporate office leases and ground leases, on its consolidated balance sheets. Further, as a result of adoption, the Company may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under certain leasing arrangements with no net impact to net income.

In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”) that allows lessors to elect, as a practical expedient, not to separate lease and nonlease components (such as services rendered) in a contract for the purpose of revenue recognition and disclosure. The practical expedient can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease

components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. Further, ASU 2018-11 also provides for an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to elect this practical expedient and apply the optional transition method for its operating leases for which the Company is the lessee, using the cumulative-effect adjustment to the opening balance sheet as of January 1, 2019. The Company is still evaluating the full impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

Table of Contents

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold in current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. ASU 2016-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

3. CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS

CCP Merger

On August 17, 2017, the Company completed the CCP Merger. Under the terms of the Merger Agreement, each share of CCP common stock issued and outstanding immediately prior to the effective time of the CCP Merger (other than any shares owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, resulting in the issuance of approximately 94.0 million shares of Company common stock at the effective time of the CCP Merger. As a result of the CCP Merger, the Company acquired 330 properties (consisting of 296 skilled nursing/transitional care facilities, 13 senior housing communities and 21 specialty hospitals and other facilities), one skilled nursing/transitional care facility leased to an operator under a direct financing lease (see Note 2, “Summary of Significant Accounting Policies—Net Investment in Direct Financing Lease”), 18 investments in loans receivable (see Note 6, “Loans Receivable and Other Investments”) and one specialty valuation firm that was subsequently sold in March 2018. Sabra also assumed certain outstanding equity awards and other debt and liabilities of CCP (see Note 7, “Debt”). Based on the closing price of Sabra’s common stock on August 16, 2017, the Company estimates the fair value of the consideration exchanged or assumed to be approximately \$2.1 billion.

The following table summarizes the purchase price allocation for the CCP Merger based on the Company’s valuation, including estimates and assumptions of the acquisition date fair value of the tangible and intangible assets acquired and liabilities assumed on August 17, 2017 (in thousands):

Real estate investments	\$3,727,310
Loans receivable and other investments	58,244
Cash and cash equivalents	77,859
Restricted cash	779
Lease intangible assets, net	145,786
Accounts receivable, prepaid expenses and other assets, net	35,873
Secured debt, net	(98,500)
Revolving credit facility	(362,000)
Unsecured term loans	(674,000)
Senior unsecured notes, net	(616,873)
Accounts payable and accrued liabilities	(134,802)
Lease intangible liabilities, net	(102,643)
Noncontrolling interests	(4,455)
Total consideration	\$2,052,578

The lease intangible assets and lease intangible liabilities acquired in connection with the CCP Merger have weighted-average amortization periods as of the closing date of the CCP Merger of 10 years.

Table of Contents

Recent Real Estate Acquisitions

During the six months ended June 30, 2018, the Company acquired 11 Senior Housing - Managed communities, five senior housing communities and two skilled nursing/transitional care facilities. During the six months ended June 30, 2017, the Company acquired one senior housing community. The consideration was allocated based on certain valuations and analyses. Certain valuations and analyses related to acquisitions during the six months ended June 30, 2018 have yet to be finalized, and accordingly, the allocations are subject to adjustment once the analyses are completed. Allocation of the consideration is as follows (in thousands):

	Six Months Ended	
	June 30,	
	2018	2017
Land	\$24,356	\$1,034
Building and improvements	187,903	13,128
Tenant origination and absorption costs intangible assets	1,312	223
Tenant relationship intangible assets	412	71
Total consideration	\$213,983	\$14,456

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets acquired in connection with these acquisitions have weighted-average amortization periods as of the respective dates of acquisition of 13 years and 22 years, respectively, for acquisitions completed during the six months ended June 30, 2018, and 15 years and 25 years, respectively, for the acquisition completed during the six months ended June 30, 2017.

For the three and six months ended June 30, 2018, the Company recognized \$10.7 million and \$20.4 million of total revenues, respectively, and \$1.6 million and \$2.5 million of net income attributable to common stockholders, respectively, from the facilities acquired during the six months ended June 30, 2018. For both the three and six months ended June 30, 2017, the Company recognized \$0.1 million of total revenues and net income attributable to common stockholders from the facility acquired during the six months ended June 30, 2017.

4. REAL ESTATE PROPERTIES HELD FOR INVESTMENT

The Company's real estate properties held for investment consisted of the following (dollars in thousands):
As of June 30, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost	Total Accumulated Depreciation	Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	352	40,077	\$4,242,748	\$(223,777)	\$4,018,971
Senior Housing - Leased	89	7,156	1,200,923	(113,020)	1,087,903
Senior Housing - Managed	24	1,712	308,221	(15,961)	292,260
Specialty Hospitals and Other	22	1,085	618,316	(24,109)	594,207
	487	50,030	6,370,208	(376,867)	5,993,341
Corporate Level			633	(292)	341
			\$6,370,841	\$(377,159)	\$5,993,682

Table of Contents

As of December 31, 2017

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost	Accumulated Depreciation	Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	384	43,223	\$4,364,387	\$ (209,039)	\$4,155,348
Senior Housing - Leased	88	8,137	1,166,687	(102,370)	1,064,317
Senior Housing - Managed	13	1,113	189,120	(12,125)	176,995
Specialty Hospitals and Other	22	1,085	614,068	(16,620)	597,448
	507	53,558	6,334,262	(340,154)	5,994,108
Corporate Level			593	(269)	324
			\$6,334,855	\$ (340,423)	\$5,994,432

	June 30, 2018	December 31, 2017
Building and improvements	\$5,489,087	\$5,449,415
Furniture and equipment	236,838	232,889
Land improvements	1,971	3,456
Land	642,945	649,095
	6,370,841	6,334,855
Accumulated depreciation	(377,159)	(340,423)
	\$5,993,682	\$5,994,432

Operating Leases

As of June 30, 2018, the substantial majority of the Company's real estate properties (excluding 24 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of June 30, 2018, the leases had a weighted-average remaining term of nine years. The leases include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled \$17.9 million and \$20.3 million as of June 30, 2018 and December 31, 2017, respectively, and letters of credit deposited with the Company totaled approximately \$90 million and \$96 million as of June 30, 2018 and December 31, 2017, respectively. In addition, our tenants have deposited with the Company \$28.0 million and \$28.3 million as of June 30, 2018 and December 31, 2017, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to our properties and their operations.

As of June 30, 2018, the Company had a \$1.1 million reserve for unpaid cash rental income and a \$3.2 million reserve associated with accumulated straight-line rental income. As of December 31, 2017, the Company had a \$3.2 million reserve for unpaid cash rental income and a \$12.4 million reserve associated with accumulated straight-line rental income.

The Company has entered into memoranda of understanding with Genesis to market for sale up to all of its remaining Genesis facilities and to restructure its lease agreements with Genesis to increase the marketability of these facilities to potential buyers. Effective January 1, 2018, the annual base rent payable under the Genesis leases was reduced by \$19.0 million pursuant to a lease restructuring agreement. During the six months ended June 30, 2018, the Company completed the sale of 27 facilities leased to Genesis and expects to complete the sale of 19 of its remaining 27 Genesis facilities during the remainder of 2018 and to retain eight facilities, although it cannot provide assurance that the sales will be completed in that timeframe, if at all.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants' financial performance,

including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company's tenants, the primary basis for the Company's evaluation of the credit quality of its tenants (and more specifically the tenant's ability to pay their rent obligations to the Company) is the tenant's lease coverage ratio or the parent's fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent ("EBITDAR") to rent and earnings before interest,

Table of Contents

taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

For both the three and six months ended June 30, 2018, no tenant relationship represented 10% or more of the Company’s total revenues.

As of June 30, 2018, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands):

July 1 through December 31, 2018	\$260,307
2019	529,844
2020	522,304
2021	520,553
2022	512,680
Thereafter	3,083,776
	\$5,429,464

5. ASSET HELD FOR SALE AND DISPOSITIONS

Asset Held for Sale

As of June 30, 2018, the Company determined that one skilled nursing/transitional care facility, with a net book value of \$6.0 million, met the criteria to be classified as held for sale. The net book value is included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. The facility was sold on July 2, 2018 for a gross sales price of \$7.0 million.

2018 Dispositions

During the six months ended June 30, 2018, the Company completed the sale of 33 skilled nursing/transitional care facilities and four senior housing communities for aggregate consideration, net of closing costs, of \$278.3 million. The net carrying value of the assets and liabilities of these facilities was \$135.8 million, which resulted in an aggregate \$142.5 million net gain on sale. The Company also recognized \$0.1 million of additional selling expenses for sales completed in 2017.

During the six months ended June 30, 2018, the Company recognized a \$1.4 million real estate impairment, of which \$0.5 million related to one senior housing community sold during the period.

Excluding the net gain on sale and real estate impairment, the Company recognized \$11.6 million and \$15.4 million of net income during the six months ended June 30, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2017 Disposition

During the six months ended June 30, 2017, the Company completed the sale of one skilled nursing/transitional care facility for consideration, net of closing costs, of \$6.1 million. The net carrying value of the assets and liabilities of this facility was \$2.1 million, which resulted in a \$4.0 million net gain on sale.

Excluding the net gain on sale, the Company recognized \$0.1 million of net income during the six months ended June 30, 2017 from this facility. The sale of this facility does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to this facility have remained in continuing operations.

Table of Contents

6. LOANS RECEIVABLE AND OTHER INVESTMENTS

As of June 30, 2018 and December 31, 2017, the Company's loans receivable and other investments consisted of the following (dollars in thousands):

Investment	Quantity as of June 30, 2018	Property Type	Principal Balance as of June 30, 2018 ⁽¹⁾	Book Value as of June 30, 2018	Book Value as of December 31, 2017	June 30, 2018 Weighted Average Contract Interest Rate / Rate of Return	June 30, 2018 Weighted Average Annualized Effective Interest Rate / Rate of Return	Maturity Date as of June 30, 2018
Loans Receivable:								
Mortgage	1	Specialty Hospital	\$15,332	\$15,332	\$12,351	10.0%	10.0 %	01/31/27
Construction	2	Senior Housing	3,989	4,055	2,733	8.0 %	7.8 %	04/30/21- 09/30/22
Mezzanine	1	Skilled Nursing	25,000	2,301	10,239	10.0%	41.9 %	05/25/20
Pre-development	1	Senior Housing	2,357	2,357	2,357	9.0 %	8.4 %	04/01/20
Other	17	Multiple	34,009	32,191	38,324	8.5 %	9.7 %	12/31/17- 04/30/27
	22		80,687	56,236	66,004	9.3 %	10.9 %	
Loan loss reserve			—	(356)	(97)			
			\$80,687	\$55,880	\$65,907			
Other Investments:								
Preferred Equity	13	Skilled Nursing / Senior Housing	50,856	51,348	48,483	12.6%	12.6 %	N/A
Total	35		\$131,543	\$107,228	\$114,390	10.6%	11.7 %	

(1) Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

In connection with the CCP Merger, the Company acquired 18 loans receivable investments with a principal balance of \$83.3 million and fair value of \$58.2 million as of August 17, 2017.

Of the loans acquired in connection with the CCP Merger, eight loans receivable investments with a principal balance of \$36.3 million were considered to have deteriorated credit quality, and based on the collateral or expected cash flows, the fair value was determined to be \$11.3 million and the accretable yield was \$3.5 million as of August 17, 2017. During the six months ended June 30, 2018, one loan with deteriorated credit quality was repaid in full. As of June 30, 2018 and December 31, 2017, the book value of these loans was \$4.8 million and \$10.0 million, respectively. The following table presents changes in the accretable yield for the three and six months ended June 30, 2018 (in thousands):

	Three Months Ended June 30, 2018	Six Months Ended June 30, 2018
Accretable yield, beginning of period	\$1,883	\$2,483

Edgar Filing: Sabra Health Care REIT, Inc. - Form 10-Q

Accretion recognized in earnings	(1,529)	(2,129)
Net reclassification from nonaccretable difference	727	727
Accretable yield, end of period	\$ 1,081	\$ 1,081

During the three and six months ended June 30, 2018, the Company recorded no provision for specific loan losses and increased its portfolio-based loan loss reserve by \$0.2 million and \$0.3 million, respectively.

As of June 30, 2018, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was \$0.4 million. As of June 30, 2018, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of \$0 and three preferred equity investments totaling \$14.5 million were on nonaccrual status. Additionally, as of June 30, 2018, the Company recognized interest income related to four loans receivable, with an aggregate book value of \$10.6 million, that were more than 90 days past due.

Table of Contents

As of December 31, 2017, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was \$0.1 million. As of December 31, 2017, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of \$0 was on nonaccrual status.

During the three and six months ended June 30, 2017, the Company recorded a provision for specific loan losses of \$0.3 million and \$1.8 million, respectively, related to five loans receivable investments, two of which were written-off during the three months ended June 30, 2017, and reduced its portfolio-based loan loss reserve by \$0.1 million and \$0.2 million, respectively.

7. DEBT

Secured Indebtedness

The Company's secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of June 30, 2018 ⁽¹⁾	Principal Balance as of December 31, 2017 ⁽¹⁾	Weighted Average Effective Interest Rate at June 30, 2018 ⁽²⁾	Maturity Date
Fixed Rate	\$157,781	\$160,702	3.87 %	December 2021 - August 2051
Variable Rate	98,500	98,500	3.89 %	July 2019
	\$256,281	\$259,202	3.88 %	

(1) Principal balance does not include deferred financing costs, net of \$2.7 million and \$2.8 million as of June 30, 2018 and December 31, 2017, respectively.

(2) Weighted average effective interest rate includes private mortgage insurance.

On August 17, 2017, in connection with the CCP Merger (see Note 3, "CCP Merger and Recent Real Estate Acquisitions"), the Company assumed a \$98.5 million variable rate secured term loan that bears interest at LIBOR plus 1.80% and matures in July 2019.

Senior Unsecured Notes

The Company's senior unsecured notes consist of the following (dollars in thousands):

Title	Maturity Date	Principal Balance as of June 30, 2018 ⁽¹⁾	Principal Balance as of December 31, 2017 ⁽¹⁾
5.5% senior unsecured notes due 2021 ("2021 Notes")	February 1, 2021	\$500,000	\$500,000
5.375% senior unsecured notes due 2023 ("2023 Notes")	June 1, 2023	200,000	200,000
5.125% senior unsecured notes due 2026 ("2026 Notes")	August 15, 2026	500,000	500,000
5.38% senior unsecured notes due 2027 ("2027 Notes")	May 17, 2027	100,000	100,000
		\$1,300,000	\$1,300,000

Principal balance does not include premium, net of \$15.2 million and deferred financing costs, net of \$8.4 million (1) as of June 30, 2018 and does not include premium, net of \$15.9 million and deferred financing costs, net of \$9.6 million as of December 31, 2017.

The 2021 Notes and the 2023 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the "Issuers"). The 2021 Notes accrue interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year, and the 2023 Notes accrue interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year.

The 2026 Notes and the 2027 Notes were assumed as a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”) and accrue interest at a rate of 5.125% and 5.38%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The obligations under the 2021 Notes, 2023 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and certain subsidiaries of Sabra; provided, however, that such guarantees are subject to release under certain customary circumstances. The obligations under the 2026 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances. See Note 12, “Summarized Condensed Consolidating Information” for additional information

Table of Contents

concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2021 Notes, 2023 Notes, 2026 Notes and 2027 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Facility

Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit facility (the “Credit Facility”). The Credit Facility amends and restates the prior credit facility entered into by the Borrowers in January 2016 (the “Prior Credit Facility”). The Company recognized a \$0.6 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Facility. The Credit Facility includes a \$1.0 billion revolving credit facility (the “Revolving Credit Facility”), \$1.1 billion in U.S. dollar term loans and a CAD \$125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to \$175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to \$2.5 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of August 17, 2021, and includes two six-month extension options. \$200.0 million of the U.S. dollar Term Loans has a maturity date of August 17, 2020, and the other Term Loans have a maturity date of August 17, 2022.

As of June 30, 2018, there was \$676.0 million outstanding under the Revolving Credit Facility and \$324.0 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the credit agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. As of June 30, 2018, the interest rate on the Revolving Credit Facility was 3.34%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that will range from 0.90% to 1.90% depending on the Debt Ratings.

On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD \$90.0 million of its Canadian dollar Term Loan at 1.59%. In addition, CAD \$90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for \$245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD \$35.0 million of its Canadian dollar Term Loan at 0.93%. See Note 8, “Derivative and Hedging Instruments” for further information. As a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for \$600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31%. See Note 8, “Derivative and Hedging Instruments” for further information.

The obligations of the Borrowers under the Credit Facility are guaranteed by Sabra and certain subsidiaries of Sabra. The Credit Facility contains customary covenants that include restrictions or limitations on the ability to make acquisitions and other investments, pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Facility also requires Sabra, through the Operating Partnership, to comply with specified financial

Table of Contents

covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio and a minimum tangible net worth requirement. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Credit Facility.

Interest Expense

During the three and six months ended June 30, 2018, the Company incurred interest expense of \$36.8 million and \$72.6 million, respectively, and \$15.9 million and \$31.7 million during the three and six months ended June 30, 2017, respectively. Interest expense includes non-cash interest expense of \$2.5 million and \$5.0 million for the three and six months ended June 30, 2018, respectively, and \$1.7 million and \$3.2 million for the three and six months ended June 30, 2017, respectively. As of June 30, 2018 and December 31, 2017, the Company had \$24.5 million and \$24.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company's outstanding debt as of June 30, 2018 (in thousands):

	Secured Indebtedness	Revolving Credit Facility (1)	Term Loans	Senior Notes	Total
July 1 through December 31, 2018	\$ 2,156	\$—	\$—	\$—	\$2,156
2019	102,920	—	—	—	102,920
2020	4,568	—	200,000	—	204,568
2021	19,757	676,000	—	500,000	1,195,757
2022	4,285	—	995,163	—	999,448
Thereafter	122,595	—	—	800,000	922,595
Total Debt	256,281	676,000	1,195,163	1,300,000	3,427,444
Premium, net	—	—	—	15,216	15,216
Deferred financing costs, net	(2,714)	—	(7,765)	(8,374)	(18,853)
Total Debt, Net	\$ 253,567	\$ 676,000	\$ 1,187,398	\$ 1,306,842	\$ 3,423,807

(1) Revolving Credit Facility is subject to two six-month extension options.

8. DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company's derivative financial instruments are used to manage differences in the amount of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's investments and borrowings.

Certain of the Company's foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company's functional currency, the U.S. dollar, of the Company's investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company's objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Approximately \$6.6 million of gains, which are included in accumulated other comprehensive income, as of June 30, 2018, are expected to be reclassified into earnings in the next 12 months.

Table of Contents

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivatives instruments as of the dates indicated (in thousands):

	June 30, 2018	December 31, 2017
Derivatives designated as cash flow hedges:		
Denominated in U.S. Dollars	\$845,000	\$ 845,000
Denominated in Canadian Dollars	\$125,000	\$ 125,000
Derivatives designated as net investment hedges:		
Denominated in Canadian Dollars	\$56,300	\$ 56,300
Financial instrument designated as net investment hedge:		
Denominated in Canadian Dollars	\$125,000	\$ 125,000

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at June 30, 2018 and December 31, 2017 (dollars in thousands):

Type	Designation	Count	Fair Value		Maturity Dates	Balance Sheet Location
			as of June 30, 2018	June 30, December 31, 2017		
Assets:						
Interest rate swaps	Cash flow	12	\$35,719	\$ 25,221	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	2,146	674	2025	Accounts receivable, prepaid expenses and other assets, net
			\$37,865	\$ 25,895		
Liabilities:						
CAD term loan	Net investment	1	95,163	99,588	2022	Term loans, net
			\$95,163	\$ 99,588		

The following presents the effect of the Company's derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and six months ended June 30, 2018 and 2017 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income				Income Statement Location
	Three Months Ended June 30, 2018	2017	Six Months Ended June 30, 2018	2017	
Cash Flow Hedges:					
Interest rate products	\$4,009	\$(136)	\$13,132	\$125	Interest expense
Net Investment Hedges:					

Foreign currency products	898	(242)	1,505	(1,159)	N/A
CAD term loan	1,750	(2,513)	4,425	(3,288)	N/A
	\$6,657	\$(2,891)	\$19,062	\$(4,322)	

Table of Contents

Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income					Income Statement Location
Three Months Ended June 30, 2018	2017	Six Months Ended June 30, 2018	2017		

Cash Flow Hedges:

Interest rate products	\$633	\$(399)	\$583	\$(869)	Interest expense
------------------------	-------	---------	-------	---------	------------------

Net Investment Hedges:

Foreign currency products	—	—	—	—	N/A
CAD term loan	—	—	—	—	N/A

	\$633	\$(399)	\$583	\$(869)	
--	-------	---------	-------	---------	--

The gain (loss) in the table above related to interest rate products, was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled \$36.8 million and \$72.6 million for the three and six months ended June 30, 2018, respectively, and \$15.9 million and \$31.7 million for the three and six months ended June 30, 2017, respectively.

During the three and six months ended June 30, 2018, no cash flow hedges were determined to be ineffective. During the three and six months ended June 30, 2017, the Company determined that a portion of a cash flow hedge was ineffective and recognized \$14,000 and \$0.1 million, respectively, of unrealized losses related to its interest rate swaps to other income in the condensed consolidated statements of income.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company's derivatives as of June 30, 2018 and December 31, 2017 (in thousands):

As of June 30, 2018

	Gross Amounts of Recognized Assets / Liabilities	Gross Amounts Offset in Balance Sheet	Net Amounts of Assets / Liabilities presented in the Balance Sheet	Gross Amounts Not Offset in the Balance Sheet		Net Amount
				Financial Instruments	Cash Collateral Received	
Offsetting Assets:						
Derivatives	\$37,865	\$	—\$ 37,865	\$	—\$	—\$37,865
Offsetting Liabilities:						
Derivatives	\$—	\$	—\$ —	\$	—\$	—\$—

As of December 31, 2017

	Gross Amounts of Recognized Assets / Liabilities	Gross Amounts Offset in Balance Sheet	Net Amounts of Assets / Liabilities	Gross Amounts Not Offset in the Balance Sheet	
				Financial Instruments	Cash Collateral Received

Edgar Filing: Sabra Health Care REIT, Inc. - Form 10-Q

	Assets / Liabilities	Balance Sheet	presented in the Balance Sheet	Financial Instrument	Cash Collateral Received	Net Amount
Offsetting Assets:						
Derivatives	\$25,895	\$	—\$ 25,895	\$	— \$	—\$25,895
Offsetting Liabilities:						
Derivatives	\$—	\$	—\$ —	\$	— \$	—\$—

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender.

As of June 30, 2018, the Company had no derivatives with a fair value in a net liability position.

Table of Contents

9. FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company's financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company's derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company's secured debt were estimated using a discounted cash flow analysis based on management's estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Table of Contents

The following are the face values, carrying amounts and fair values of the Company's financial instruments as of June 30, 2018 and December 31, 2017 whose carrying amounts do not approximate their fair value (in thousands):

	June 30, 2018			December 31, 2017		
	Face Value (1)	Carrying Amount (2)	Fair Value	Face Value (1)	Carrying Amount (2)	Fair Value
Financial assets:						
Loans receivable	\$80,687	\$ 55,880	\$ 58,656	\$91,280	\$ 65,907	\$ 65,892
Preferred equity investments	50,856	51,348	50,787	48,035	48,483	47,064
Financial liabilities:						
Senior Notes	1,300,000	1,306,842	1,292,347	1,300,000	1,306,286	1,329,191
Secured indebtedness	256,281	253,567	236,862	259,202	256,430	246,461

(1) Face value represents amounts contractually due under the terms of the respective agreements.

(2) Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of June 30, 2018 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

	Fair Value Measurements		
	Total	Using Quoted Prices in Active Markets for Identical Assets (Level 1)	Using Significant Other Observable Inputs (Level 2)
Financial assets:			
Loans receivable	\$ 58,656	\$ —	\$ 58,656
Preferred equity investments	50,787	—	50,787
Financial liabilities:			
Senior Notes	1,292,347	—	1,292,347
Secured indebtedness	236,862	—	236,862

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company's estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the six months ended June 30, 2018, the Company recorded the following amounts measured at fair value (in thousands):

	Fair Value Measurements		
	Total	Using Quoted Prices in Active Markets for Identical Assets (Level 1)	Using Significant Other Observable Inputs (Level 2)
Financial assets:			
Loans receivable	\$ 58,656	\$ —	\$ 58,656
Preferred equity investments	50,787	—	50,787
Financial liabilities:			
Senior Notes	1,292,347	—	1,292,347
Secured indebtedness	236,862	—	236,862

Markets)
 for
 Identical
 Assets
 (Level
 1)

Recurring Basis:

Financial assets:

Interest rate swap	\$35,719	\$-35,719	\$	—
Cross currency swap	2,146	—2,146	—	—

Table of Contents

10. EQUITY

Preferred Stock

On March 21, 2013, the Company completed an underwritten public offering of 5,750,000 shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) at a price of \$25.00 per share, pursuant to an effective registration statement. The Company received net proceeds of \$138.3 million from the offering, after deducting underwriting discounts and other offering expenses. The Company classified the par value as preferred equity on its condensed consolidated balance sheets with the balance of the liquidation preference, net of any issuance costs, recorded as an increase in paid-in capital.

The Company redeemed all 5,750,000 shares of its Series A Preferred Stock on June 1, 2018 (the “Redemption Date”) for \$25.00 per share, plus accrued and unpaid dividends to, but not including, the Redemption Date, without interest, in the amount of \$0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to \$25.4453125. As a result of the redemption, the Company incurred a charge of \$5.5 million related to the original issuance costs of the Series A Preferred Stock. The charge is presented as an additional preferred stock dividend in the Company’s condensed consolidated statements of income.

Common Stock

As a result of the CCP Merger completed on August 17, 2017, the Company issued approximately 94.0 million shares of its common stock in exchange for shares of CCP common stock and shares underlying share-based awards assumed by the Company outstanding as of the effective time of the CCP Merger.

On September 28, 2017, the Company completed an underwritten public offering of 16.0 million newly issued shares of its common stock pursuant to an effective registration statement. The underwriters exercised their option to purchase additional shares, and on October 2, 2017, the Company issued an additional 2.4 million newly issued shares of its common stock pursuant to an effective registration statement. The Company received net proceeds, before expenses, of \$370.9 million from the offering, after giving effect to the issuance and sale of all 18.4 million shares of common stock, at a price of \$21.00 per share. These proceeds were used to repay borrowings outstanding under the Revolving Credit Facility.

The following table lists the cash dividends on common stock declared and paid by the Company during the six months ended June 30, 2018:

Declaration Date	Record Date	Amount	
		Per Share	Dividend Payable Date
February 5, 2018	February 15, 2018	\$ 0.45	February 28, 2018
May 9, 2018	May 21, 2018	\$ 0.45	May 31, 2018

During the six months ended June 30, 2018, the Company issued 27,747 shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the six months ended June 30, 2018 and 2017, the Company incurred \$0.2 million and \$2.6 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	June 30, 2018	December 31, 2017
Foreign currency translation loss	\$(3,026)	\$(2,913)
Unrealized gains on cash flow hedges	27,438	14,202
Total accumulated other comprehensive income	\$24,412	\$ 11,289

Table of Contents

11. EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except share and per share amounts):

	Three Months Ended		Six Months Ended	
	June 30, 2018	2017	June 30, 2018	2017
Numerator				
Net income attributable to common stockholders	\$ 193,580	\$ 17,960	\$ 253,490	\$ 34,222
Denominator				
Basic weighted average common shares and common equivalents	178,314,750	155,438,739	178,304,736	155,396,146
Dilutive restricted stock units	369,274	232,114	296,056	297,873
Diluted weighted average common shares	178,684,024	155,670,853	178,600,792	155,694,019
Net income attributable to common stockholders, per:				
Basic common share	\$ 1.09	\$ 0.27	\$ 1.42	\$ 0.52
Diluted common share	\$ 1.08	\$ 0.27	\$ 1.42	\$ 0.52

During the three and six months ended June 30, 2018, approximately 35,300 and 46,000 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and six months ended June 30, 2017, approximately 15,900 and 19,300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were considered anti-dilutive during the three and six months ended June 30, 2018, and no stock options were outstanding during the three and six months ended June 30, 2017.

12. SUMMARIZED CONDENSED CONSOLIDATING INFORMATION

In connection with the offerings of the 2021 Notes and the 2023 Notes by the Issuers, the Company and certain 100% owned subsidiaries of the Company (the "Guarantors") have, jointly and severally, fully and unconditionally guaranteed the 2021 Notes and the 2023 Notes, subject to release under certain customary circumstances as described below. In connection with the assumption of the 2026 Notes as a result of the CCP Merger (see Note 3, "CCP Merger and Recent Real Estate Acquisitions"), the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. These guarantees are subordinated to all existing and future senior debt and senior guarantees of the Guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company's ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries.

A Guarantor will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2021 Notes and the 2023 Notes in the event of:

- Any sale of the subsidiary Guarantor or of all or substantially all of its assets;
- A merger or consolidation of a subsidiary Guarantor with an issuer of the 2021 Notes or the 2023 Notes or another Guarantor, provided that the surviving entity remains a Guarantor;
- A subsidiary Guarantor is declared "unrestricted" for covenant purposes under the indentures governing the 2021 Notes or the 2023 Notes;
- The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2021 Notes or the 2023 Notes have been satisfied;
-

A liquidation or dissolution, to the extent permitted under the indentures governing the 2021 Notes or the 2023 Notes, of a subsidiary Guarantor; or

• The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty.

Table of Contents

The Company will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2026 Notes in the event of:

- A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;
- A merger or consolidation, provided that the surviving entity remains a Guarantor; or
- The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to Rule 3-10 of Regulation S-X, the following summarized condensed consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Capital Corporation, the Guarantors, and the Company’s non-Guarantor subsidiaries with respect to the 2021 Notes and the 2023 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Capital Corporation, the Guarantors and the non-Guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Capital Corporation, the Guarantors or non-Guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. The Guarantor subsidiaries’ investments in the non-Guarantor subsidiaries and non-Guarantor subsidiaries’ investments in Guarantor subsidiaries are presented under the equity method of accounting. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the condensed consolidating statement of cash flows.

Condensed consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Capital Corporation only, the combined Guarantor subsidiaries and the combined non-Guarantor subsidiaries, are as follows:

Table of Contents

CONDENSED CONSOLIDATING BALANCE SHEET

June 30, 2018

(in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Corporation ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾ Combined Guarantor Subsidiaries of 2021 Notes ⁽³⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Assets							
Real estate investments, net of accumulated depreciation	\$ 341	\$ —	\$ —	\$ 1,666,116	\$ 4,327,225	\$ —	\$ 5,993,682
Loans receivable and other investments, net	(356)) —	—	52,315	55,269	—	107,228
Investment in unconsolidated joint venture	—	—	—	—	348,950	—	348,950
Cash and cash equivalents	31,269	—	—	1,405	6,135	—	38,809
Restricted cash	—	—	—	174,913	11,932	—	186,845
Lease intangible assets, net	—	—	—	16,815	139,451	—	156,266
Accounts receivable, prepaid expenses and other assets, net	(536)) 46,700	—	84,809	73,017	(7,626)) 196,364
Intercompany	2,186,044	2,727,032	—	—	—	(4,913,076)) —
Investment in subsidiaries	1,209,953	1,538,155	—	15,830	—	(2,763,938)) —
Total assets	\$ 3,426,715	\$ 4,311,887	\$ —	\$ 2,012,203	\$ 4,961,979	\$ (7,684,640)	\$ 7,028,144
Liabilities							
Secured debt, net	\$ —	\$ —	\$ —	\$ —	\$ 253,567	\$ —	\$ 253,567
Revolving credit facility	—	676,000	—	—	—	—	676,000
Term loans, net	—	1,093,314	—	94,084	—	—	1,187,398
Senior unsecured notes, net	—	1,306,842	—	—	—	—	1,306,842
Accounts payable and accrued liabilities	23,172	25,778	—	3,576	60,439	(7,626)) 105,339
Lease intangible liabilities, net	—	—	—	—	91,073	—	91,073
Intercompany	—	—	—	636,037	4,277,039	(4,913,076)) —
Total liabilities	23,172	3,101,934	—	733,697	4,682,118	(4,920,702)	3,620,219
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543	1,209,953	—	1,278,506	275,479	(2,763,938)	3,403,543
Noncontrolling interests	—	—	—	—	4,382	—	4,382
Total equity	3,403,543	1,209,953	—	1,278,506	279,861	(2,763,938)	3,407,925
Total liabilities and equity	\$ 3,426,715	\$ 4,311,887	\$ —	\$ 2,012,203	\$ 4,961,979	\$ (7,684,640)	\$ 7,028,144

(1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

(2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

(3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

(4)

The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

- (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.
- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING BALANCE SHEET

December 31, 2017

(in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Combined Sabra Capital Corporation ⁽³⁾ 2023 Notes ⁽⁴⁾	Combined Guarantor Subsidiaries of 2021 Notes ⁽⁵⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁶⁾	Elimination	Consolidated
Assets							
Real estate investments, net of accumulated depreciation	\$324	\$—	\$—	\$1,756,933	\$4,237,175	\$—	\$5,994,432
Loans receivable and other investments, net	(97)) —	—	55,297	59,190	—	114,390
Cash and cash equivalents	511,670	—	—	449	6,513	—	518,632
Restricted cash	—	—	—	36,910	31,907	—	68,817
Lease intangible assets, net	—	—	—	17,577	149,542	—	167,119
Accounts receivable, prepaid expenses and other assets, net	3,499	36,073	—	80,739	53,765	(5,189)) 168,887
Intercompany	2,043,402	2,721,979	—	—	—	(4,765,381)) —
Investment in subsidiaries	890,462	1,198,305	—	14,661	—	(2,103,428)) —
Total assets	\$3,449,260	\$3,956,357	\$—	\$1,962,566	\$4,538,092	\$(6,873,998)	\$7,032,277
Liabilities							
Secured debt, net	\$—	\$—	\$—	\$—	\$256,430	\$—	\$256,430
Revolving credit facility	—	641,000	—	—	—	—	641,000
Term loans, net	—	1,092,397	—	98,377	—	—	1,190,774
Senior unsecured notes, net	—	1,306,286	—	—	—	—	1,306,286
Accounts payable and accrued liabilities	16,453	26,212	—	3,560	61,487	(5,189)) 102,523
Lease intangible liabilities, net	—	—	—	—	98,015	—	98,015
Intercompany	—	—	—	785,120	3,980,261	(4,765,381)) —
Total liabilities	16,453	3,065,895	—	887,057	4,396,193	(4,770,570)	3,595,028
Total Sabra Health Care REIT, Inc. stockholders' equity	3,432,807	890,462	—	1,075,509	137,457	(2,103,428)) 3,432,807
Noncontrolling interests	—	—	—	—	4,442	—	4,442
Total equity	3,432,807	890,462	—	1,075,509	141,899	(2,103,428)) 3,437,249
Total liabilities and equity	\$3,449,260	\$3,956,357	\$—	\$1,962,566	\$4,538,092	\$(6,873,998)	\$7,032,277

(1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

(2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

(3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

(4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

(5)

The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months Ended June 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Construction 2023 Notes ⁽⁴⁾	Combined Guarantor Subsidiaries of 2021 Notes ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾	Combined Non-Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Revenues:								
Rental income	\$—	\$—	\$—	\$44,560	\$ 103,989	\$(4,320))	\$ 144,229
Interest and other income	40	96	—	1,198	3,315	(96))	4,553
Resident fees and services	—	—	—	—	17,530	—		17,530
Total revenues	40	96	—	45,758	124,834	(4,416))	166,312
Expenses:								
Depreciation and amortization	222	—	—	14,146	32,460	—		46,828
Interest	—	33,415	—	810	2,628	(96))	36,757
Operating expenses	—	—	—	—	16,619	(4,320))	12,299
General and administrative	8,009	14	—	379	869	—		9,271
Merger and acquisition costs	112	—	—	—	—	—		112
Provision for (recovery of) doubtful accounts and loan losses	311	—	—	(985))	—		(674)
Impairment of real estate	—	—	—	881	—	—		881
Total expenses	8,654	33,429	—	15,231	52,576	(4,416))	105,474
Other income:								
Other income (expense)	—	32	—	(32))	—		—
Net gain on sales of real estate	—	—	—	141,918	985	—		142,903
Total other income	—	32	—	141,886	985	—		142,903
Income in subsidiary	209,456	242,758	—	1,871	—	(454,085))	—
Income before loss from unconsolidated joint venture and income tax expense	200,842	209,457	—	174,284	73,243	(454,085))	203,741
Loss from unconsolidated joint venture	—	—	—	—	(2,347))		(2,347)
Income tax expense	(55)) (1))	(489)) (60))		(605)
Net income	200,787	209,456	—	173,795	70,836	(454,085))	200,789
Net income attributable to noncontrolling interests	—	—	—	—	(2))		(2)
Net income attributable to Sabra Health Care REIT, Inc.	200,787	209,456	—	173,795	70,834	(454,085))	200,787
Preferred stock dividends	(7,207))	—	—	—	—		(7,207)
Net income attributable to common stockholders	\$ 193,580	\$ 209,456	\$—	\$ 173,795	\$ 70,834	\$(454,085))	\$ 193,580

Net income attributable to common stockholders, per:	
Basic common share	\$ 1.09
Diluted common share	\$ 1.08
Weighted-average number of common shares outstanding, basic	178,314,750
Weighted-average number of common shares outstanding, diluted	178,684,024

- (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.
- (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.
- (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.
- (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.
- (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.
- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months Ended June 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Company ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2021 Notes ⁽⁴⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and Notes ⁽⁵⁾	Elimination	Consolidated
Revenues:							
Rental income	\$ —	\$ —	\$ —	\$ 52,442	\$ 4,656	\$(1,194)	\$ 55,904
Interest and other income	6	—	—	2,039	—	(18)	2,027
Resident fees and services	—	—	—	—	6,805	—	6,805
Total revenues	6	—	—	54,481	11,461	(1,212)	64,736
Expenses:							
Depreciation and amortization	216	—	—	15,425	1,579	—	17,220
Interest	—	13,516	—	715	1,631	—	15,862
Operating expenses	—	—	—	—	5,619	(1,212)	4,407
General and administrative	4,063	17	—	991	55	—	5,126
Merger and acquisition costs	5,883	—	—	4	—	—	5,887
Provision for doubtful accounts and loan losses	227	—	—	308	—	—	535
Total expenses	10,389	13,533	—	17,443	8,884	(1,212)	49,037
Other income (expense):							
Other income (expense)	916	703	—	(665)	(13)	—	941
Net gain on sales of real estate	—	—	—	4,026	6	—	4,032
Total other income (expense)	916	703	—	3,361	(7)	—	4,973
Income in subsidiary	29,894	42,724	—	1,785	—	(74,403)	—
Income before income tax benefit (expense)	20,427	29,894	—	42,184	2,570	(74,403)	20,672
Income tax benefit (expense)	93	—	—	(227)	(2)	—	(136)
Net income	20,520	29,894	—	41,957	2,568	(74,403)	20,536
Net income attributable to noncontrolling interests	—	—	—	—	(16)	—	(16)
Net income attributable to Sabra Health Care REIT, Inc.	20,520	29,894	—	41,957	2,552	(74,403)	20,520
Preferred stock dividends	(2,560)	—	—	—	—	—	(2,560)
Net income attributable to common stockholders	\$ 17,960	\$ 29,894	\$ —	\$ 41,957	\$ 2,552	\$(74,403)	\$ 17,960
Net income attributable to common stockholders, per:							
Basic common share							\$ 0.27
Diluted common share							\$ 0.27

Weighted-average number of common shares outstanding, basic	65,438,739
Weighted-average number of common shares outstanding, diluted	65,670,853

- (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.
- (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.
- (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.
- (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.
- (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.
- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months Ended June 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Construction 2023 Notes ⁽⁴⁾	Combined Guarantor Subsidiaries of 2021 Notes ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾ Combined Non-Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Revenues:							
Rental income	\$—	\$—	\$—	\$90,024	\$ 207,013	\$(8,553)	\$ 288,484
Interest and other income	50	208	—	2,465	6,376	(208)	8,891
Resident fees and services	—	—	—	—	35,023	—	35,023
Total revenues	50	208	—	92,489	248,412	(8,761)	332,398
Expenses:							
Depreciation and amortization	443	—	—	29,076	65,314	—	94,833
Interest	—	65,980	—	1,601	5,202	(208)	72,575
Operating expenses	—	—	—	—	32,976	(8,553)	24,423
General and administrative	13,831	29	—	810	2,468	—	17,138
Merger and acquisition costs	448	—	—	—	(6))	442
Provision for (recovery of) doubtful accounts and loan losses	2,492	—	—	(1,956)) 3	—	539
Impairment of real estate	—	—	—	1,413	—	—	1,413
Total expenses	17,214	66,009	—	30,944	105,957	(8,761)	211,363
Other income:							
Other income	1,977	233	—	378	232	—	2,820
Net gain on sales of real estate	—	—	—	141,862	569	—	142,431
Total other income	1,977	233	—	142,240	801	—	145,251
Income in subsidiary	278,798	344,367	—	3,725	—	(626,890)	—
Income before loss from unconsolidated joint venture and income tax expense	263,611	278,799	—	207,510	143,256	(626,890)	266,286
Loss from unconsolidated joint venture	—	—	—	—	(1,901))	(1,901)
Income tax expense	(353)) (1))	(542)) (219))	(1,115)
Net income	263,258	278,798	—	206,968	141,136	(626,890)	263,270
Net income attributable to noncontrolling interests	—	—	—	—	(12))	(12)
Net income attributable to Sabra Health Care REIT, Inc.	263,258	278,798	—	206,968	141,124	(626,890)	263,258
Preferred stock dividends	(9,768))	—	—	—	—	(9,768)
Net income attributable to common stockholders	\$ 253,490	\$ 278,798	\$—	\$ 206,968	\$ 141,124	\$(626,890)	\$ 253,490
Net income attributable to common stockholders, per:							

Basic common share	\$ 1.42
Diluted common share	\$ 1.42
Weighted-average number of common shares outstanding, basic	178,304,733
Weighted-average number of common shares outstanding, diluted	178,600,789

- (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.
- (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.
- (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.
- (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.
- (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.
- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months Ended June 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Connection ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁴⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Revenues:								
Rental income	\$ —	\$ —	\$ —	\$ 105,481	\$ 9,625	\$ (1,978))	\$ 113,128
Interest and other income	13	—	—	3,977	—	(18))	3,972
Resident fees and services	—	—	—	—	10,286	—)	10,286
Total revenues	13	—	—	109,458	19,911	(1,996))	127,386
Expenses:								
Depreciation and amortization	432	—	—	32,381	3,544	—)	36,357
Interest	—	26,924	—	1,445	3,281	—)	31,650
Operating expenses	—	—	—	—	8,823	(1,996))	6,827
General and administrative	9,322	31	—	1,758	104	—)	11,215
Merger and acquisition costs	6,417	—	—	34	—	—)	6,451
Provision for doubtful accounts and loan losses	82	—	—	2,223	—	—)	2,305
Total expenses	16,253	26,955	—	37,841	15,752	(1,996))	94,805
Other income:								
Other income	2,283	737	—	50	—	—)	3,070
Net gain on sales of real estate	—	—	—	4,026	6	—)	4,032
Total other income	2,283	737	—	4,076	6	—)	7,102
Income in subsidiary	53,331	79,550	—	3,564	—	(136,445))	—
Income before income tax expense	39,374	53,332	—	79,257	4,165	(136,445))	39,683
Income tax expense	(31)	(1)	—	(227)	(97)	—)	(356)
Net income	39,343	53,331	—	79,030	4,068	(136,445))	39,327
Net loss attributable to noncontrolling interests	—	—	—	—	16	—)	16
Net income attributable to Sabra Health Care REIT, Inc.	39,343	53,331	—	79,030	4,084	(136,445))	39,343
Preferred stock dividends	(5,121)	—	—	—	—	—)	(5,121)
Net income attributable to common stockholders	\$ 34,222	\$ 53,331	\$ —	\$ 79,030	\$ 4,084	\$ (136,445))	\$ 34,222
Net income attributable to common stockholders, per:								
Basic common share								\$ 0.52
Diluted common share								\$ 0.52
Weighted-average number of common shares outstanding, basic								65,396,146

Weighted-average number of
common shares outstanding, diluted 65,694,019

- (1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.
- (2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.
- (3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.
- (4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.
- (5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.
- (6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended June 30, 2018

(dollars in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Corporation ⁽³⁾	Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁴⁾	Combined Non-Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Net income	\$ 200,787	\$ 209,456	\$—	\$ 173,795	\$ 70,836	\$(454,085)	\$ 200,789
Other comprehensive income (loss):							
Unrealized gain (loss), net of tax:							
Foreign currency translation gain (loss)	—	1,064	—	(608)	(195)	—	261
Unrealized gain on cash flow hedges	—	3,335	—	3	—	—	3,338
Total other comprehensive income (loss)	—	4,399	—	(605)	(195)	—	3,599
Comprehensive income	200,787	213,855	—	173,190	70,641	(454,085)	204,388
Comprehensive income attributable to noncontrolling interest	—	—	—	—	(2)	—	(2)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	\$ 200,787	\$ 213,855	\$—	\$ 173,190	\$ 70,639	\$(454,085)	\$ 204,386

(1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

(2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

(3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

(4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

(5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

(6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended June 30, 2017

(dollars in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Corporation ⁽³⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾	Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁴⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes ⁽⁵⁾	Elimination	Consolidated
Net income	\$ 20,520	\$ 29,894	\$ —	\$ 41,957	\$ 2,568	\$ (74,403)		\$ 20,536
Other comprehensive (loss) income:								
Unrealized gain (loss), net of tax:								
Foreign currency translation (loss) gain	—	(415)	—	833	280	—		698
Unrealized gain (loss) on cash flow hedges	—	285	—	(188)	—	—		97
Total other comprehensive (loss) income	—	(130)	—	645	280	—		795
Comprehensive income	20,520	29,764	—	42,602	2,848	(74,403)		21,331
Comprehensive income attributable to noncontrolling interest	—	—	—	—	(16)	—		(16)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	\$ 20,520	\$ 29,764	\$ —	\$ 42,602	\$ 2,832	\$ (74,403)		\$ 21,315

(1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

(2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

(3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

(4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

(5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

(6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months Ended June 30, 2018

(dollars in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Sabra Capital Corporation ⁽³⁾	Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁴⁾	Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Net income	\$ 263,258	\$ 278,798	\$ —	\$ 206,968	\$ 141,136	\$ (626,890)	\$ 263,270
Other comprehensive income (loss):							
Unrealized gain (loss), net of tax:							
Foreign currency translation gain (loss)	—	1,905	—	(1,536)	(482)	—	(113)
Unrealized gain (loss) on cash flow hedges	—	13,238	—	(2)	—	—	13,236
Total other comprehensive income (loss)	—	15,143	—	(1,538)	(482)	—	13,123
Comprehensive income	263,258	293,941	—	205,430	140,654	(626,890)	276,393
Comprehensive income attributable to noncontrolling interest	—	—	—	—	(12)	—	(12)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	\$ 263,258	\$ 293,941	\$ —	\$ 205,430	\$ 140,642	\$ (626,890)	\$ 276,381

(1) The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

(2) The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

(3) Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

(4) The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

(5) The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

(6) None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Table of Contents

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months Ended June 30, 2017

(dollars in thousands)

(unaudited)

	Parent Company ⁽¹⁾	Operating Partnership ⁽²⁾	Combined Non-Guarantor Subsidiaries of 2026 Notes ⁽⁶⁾	Combined Non-Guarantor Subsidiaries of 2021 Notes and 2023 Notes ⁽⁵⁾	Elimination	Consolidated
Net income	\$ 39,343	\$ 53,331	\$ 79,030	\$ 4,068	\$(136,445)	\$ 39,327
Other comprehensive (loss) income:						
Unrealized gain (loss), net of tax:						
Foreign currency translation (loss) gain	—	(1,367)	(1,131)	376	—	140
Unrealized gain (loss) on cash flow hedges	—	1,013	(188)	—	—	—